Novo Nordisk sales beat estimates, but the story wasn’t Ozempic

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs.

Source: MarketWatch

Continue reading...